Comprehensive control of human papillomavirus infections and related diseases.
Comprehensive control of human papillomavirus infections and related diseases.
复制标题
DOI：
10.1016/j.vaccine.2013.07.026
复制
发表时间：
2013-11-22
期刊：
影响因子：
5.5
通讯作者：
de Sanjose, Silvia
中科院分区：
文献类型：
--
作者：
Xavier Bosch, F.;Broker, Thomas R.;Forman, David;Moscicki, Anna-Barbara;Gillison, Maura L.;Doorbar, John;Stern, Peter L.;Stanley, Margaret;Arbyn, Marc;Poljak, Mario;Cuzick, Jack;Castle, Philip E.;Schiller, John T.;Markowitz, Lauri E.;Fisher, William A.;Canfell, Karen;Denny, Lynette A.;Franco, Eduardo L.;Steben, Marc;Kane, Mark A.;Schiffman, Mark;Meijer, Chris J. L. M.;Sankaranarayanan, Rengaswamy;Castellsague, Xavier;Kim, Jane J.;Brotons, Maria;Alemany, Laia;Albero, Ginesa;Diaz, Mireia;de Sanjose, Silvia
关键词：
人乳头瘤病毒（HPV）感染是世界范围内公认的感染相关癌症的主要原因之一，也是其他疾病的致病因素。国际癌症研究机构已经为宫颈癌、子宫癌、阴茎癌、外阴癌、阴道癌、肛门癌和口咽癌（包括舌根和扁桃体）提供了强有力的证据，证明HPV有因果关系。在2008年全世界估计发生的1270万例新发癌症中，4.8%可归因于人乳头瘤病毒感染，发展中国家的发病率和死亡率明显高于发达国家。近年来，我们对hpv及其与宿主细胞、组织和免疫系统的相互作用有了大量的了解；已验证并实施了安全有效的预防HPV感染疫苗接种战略；开发出越来越敏感和特异的人乳头瘤病毒分子诊断工具，用于子宫颈癌筛查；并大大提高了全球对HPV及其在妇女、男子和儿童中的许多相关疾病的认识。虽然这些成就表明生物医学研究在产生重要公共卫生干预措施方面取得了成功，但它们也带来了新的艰巨挑战：人乳头瘤病毒预防和医疗保健的成本、技术上可能的实施、对预防机会的社会政治阻力，以及国家经济能力和卫生保健系统的广泛差异。本文综述了在全面控制HPV感染和HPV相关癌症及其他疾病方面的进展和面临的挑战。所提供的信息可以从预防宫颈癌和其他与人乳头瘤病毒有关的疾病的重新规划范式的角度来看待，该范式将包括至少四个主要组成部分的战略组合：1)在所有国家向妇女常规介绍人乳头瘤病毒疫苗；2)使用基于人乳头瘤病毒的技术扩展和简化现有筛查规划；3)将适应的筛查规划扩展到发展中人口；4)考虑在女性和男性中通过人乳头瘤病毒疫苗接种可预防的更广泛的癌症和其他疾病。尽管已经取得了巨大进展，但必须继续努力，包括国际宣传，以实现在发达国家和发展中国家广泛、最理想地普遍实施HPV预防战略。本文总结了一篇特殊的ICO专著“HPV感染和相关疾病的综合控制”疫苗第30卷，增刊5,2012年所呈现的章节信息。关于每个小主题的更多细节和关于支持文献参考的完整信息可以在原始章节中找到。
Infection with human papillomavirus (HPV) is recognized as one of the major causes of infection-related cancer worldwide, as well as the causal factor in other diseases. Strong evidence for a causal etiology with HPV has been stated by the International Agency for Research on Cancer for cancers of the cervix uteri, penis, vulva, vagina, anus and oropharynx (including base of the tongue and tonsils). Of the estimated 12.7 million new cancers occurring in 2008 worldwide, 4.8% were attributable to HPV infection, with substantially higher incidence and mortality rates seen in developing versus developed countries. In recent years, we have gained tremendous knowledge about HPVs and their interactions with host cells, tissues and the immune system; have validated and implemented strategies for safe and efficacious prophylactic vaccination against HPV infections; have developed increasingly sensitive and specific molecular diagnostic tools for HPV detection for use in cervical cancer screening; and have substantially increased global awareness of HPV and its many associated diseases in women, men, and children. While these achievements exemplify the success of biomedical research in generating important public health interventions, they also generate new and daunting challenges: costs of HPV prevention and medical care, the implementation of what is technically possible, socio-political resistance to prevention opportunities, and the very wide ranges of national economic capabilities and health care systems. Gains and challenges faced in the quest for comprehensive control of HPV infection and HPV-related cancers and other disease are summarized in this review. The information presented may be viewed in terms of a reframed paradigm of prevention of cervical cancer and other HPV-related diseases that will include strategic combinations of at least four major components: 1) routine introduction of HPV vaccines to women in all countries, 2) extension and simplification of existing screening programs using HPV-based technology, 3) extension of adapted screening programs to developing populations, and 4) consideration of the broader spectrum of cancers and other diseases preventable by HPV vaccination in women, as well as in men. Despite the huge advances already achieved, there must be ongoing efforts including international advocacy to achieve widespread—optimally universal—implementation of HPV prevention strategies in both developed and developing countries. This article summarizes information from the chapters presented in a special ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012. Additional details on each subtopic and full information regarding the supporting literature references may be found in the original chapters.
登录
查看更多内容
影响因子：
5.5
作者：
Moscicki AB;Schiffman M;Burchell A;Albero G;Giuliano AR;Goodman MT;Kjaer SK;Palefsky J
通讯作者：
Palefsky J
影响因子：
5.5
作者：
Franco EL;de Sanjosé S;Broker TR;Stanley MA;Chevarie-Davis M;Isidean SD;Schiffman M
通讯作者：
Schiffman M
影响因子：
5.5
作者：
Stern PL;van der Burg SH;Hampson IN;Broker TR;Fiander A;Lacey CJ;Kitchener HC;Einstein MH
通讯作者：
Einstein MH
影响因子：
5.5
作者：
Schiller JT;Castellsagué X;Garland SM
通讯作者：
Garland SM